eversyn
Magdeburg · Founded 2024
About eversyn
eversyn is a spin-off of the Max Planck Institute Magdeburg, pioneers cell-free biosynthesis, advancing beyond precision fermentation. They design multi-enzyme pathways for the efficient production of activated sugars. This patented technology breakthrough underpins their unique commercial feasibility for many high-value glycans, notably complex human milk oligosaccharides and tailored therapeutic protein glycosylation.
Company Facts
- Founded: 2024
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.0M
- Funding stage: Seed
- Last round: Seed (Jan 2024)
- Website: https://www.eversyn.de/
- Phone: +49 391 67 54 676
Industries & Categories
Biopharma, Biotechnology, Nutrition
Social Profiles
Canonical: https://fsome.com/organization/eversyn-62707 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.